ALX Oncology (ALXO) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cue Biopharma (CUE) has outperformed ALX Oncology (ALXO) over the past year, losing 13.2% versus a loss of 40.1%. Over five years, CUE leads with a -94.1% price change compared with -98.0% for ALXO. ALX Oncology is the larger company by market cap ($163.2 million vs $162.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | CUE |
|---|---|---|
| Share price | $1.18 | $22.33 |
| Market cap | $163.17M | $162.21M |
| 1-day change | +4.42% | -0.80% |
| YTD return | +4.42% | +144.04% |
| 1-year return | -40.10% | -13.25% |
| 5-year return | -98.00% | -94.09% |
| EPS (TTM) | $-1.13 | $-29.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $45.50 |
| 52-week low | $1.05 | $4.98 |
| Distance from 52-week high | -55.64% | -50.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +289.83% | +294.09% |
| Average volume | 1.04M | 267.15K |
| Shares outstanding | 138.28M | 7.26M |
| Employees | 48 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed ALXO by 26.9 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ALXO vs CUE FAQ
Which is bigger, ALX Oncology or Cue Biopharma?
ALX Oncology (ALXO) is larger, with a market capitalization of $163.17M compared with $162.21M for Cue Biopharma (CUE).
Which stock has performed better over the past year, ALXO or CUE?
CUE returned -13.25% over the past 12 months, compared with -40.10% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.